Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer

Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer

Most women with metastatic breast cancer have a response to various combinations of conventional-dose chemotherapy, but less than 5 percent of them are alive 10 years after the detection of metastatic spread. 1 Several phase 2 trials performed in the late 1980s reported promising results for high-do...

Full description

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 342; no. 15; pp. 1069 - 1076
Main Authors: Stadtmauer, Edward A, O'Neill, Anne, Goldstein, Lori J, Crilley, Pamela A, Mangan, Kenneth F, Ingle, James N, Brodsky, Isadore, Martino, Silvana, Lazarus, Hillard M, Erban, John K, Sickles, Cheryl, Luger, Selina M, Klumpp, Thomas R, Litzow, Mark R, Topolsky, David L, Glick, John H
Format: Journal Article
Language:English
Published: Boston, MA Massachusetts Medical Society 13-04-2000
Subjects:
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Bone marrow
Bone marrow, stem cells transplantation. Graft versus host reaction
Breast cancer
Chemotherapy
Medical sciences
stem cell transplantation
Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Transplants & implants
Womens health
United States > US
Philadelphia Pennsylvania
Antineoplastic agent
Human
Prognosis
Stem cell
Hematopoietic cell
Metastasis
Malignant tumor
Survival
Mammary gland diseases
Autograft
Chemotherapy
Graft
Female
Combined treatment
Mammary gland
High dose
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Most women with metastatic breast cancer have a response to various combinations of conventional-dose chemotherapy, but less than 5 percent of them are alive 10 years after the detection of metastatic spread. 1 Several phase 2 trials performed in the late 1980s reported promising results for high-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation in patients with chemotherapy-responsive metastatic breast cancer. 2 – 6 These trials consistently reported high overall rates of response (combined complete and partial responses), ranging from 73 to 100 percent. Despite a median survival of only 10 to 24 months, 7 to 18 percent of patients in these studies . . .
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM200004133421501